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Abstract
Human papillomaviruses (HPV) are the causative agents of virtually all
cervical carcinomas. Nevertheless, a small proportion of cervical cancer are
negative for HPV, although the significance of this finding remains unclear.
We aimed to provide insight into the differential clinico-pathological
characteristics of this unusual subset of HPV-negative cervical cancer. We
performed HPV-DNA detection using a highly sensitive PCR test (SPF10) and
p16 immunostaining in 214 cervical carcinomas specimens from women
treated at the Gynecological Oncology Unit of the Hospital Clinic (Barcelona,















including disease-free survival and overall survival, of HPV-negative and -
positive cervical carcinomas were compared. Twenty-one out of 214 tumors
(10%) were negative for HPV DNA. HPV-negative tumors were more
frequently of the non-squamous type (9/21, 43% vs. 37/193, 19%; p < 0.01)
and showed negative p16 staining (9/21; 43% vs. 7/193; 4%; p < 0.01). HPV-
negative tumors were more frequently diagnosed at advanced FIGO stage
(19/21, 91% vs. 110/193, 57%; p < 0.01) and more frequently had lymph node
metastases (14/21, 67% vs. 69/193, 36%; p < 0.01). Patients with HPV-
negative cervical cancer had a significantly worse disease-free survival (59.8
months, 95% confidence interval 32.0–87.6 vs. 132.2 months, 95% confidence
interval 118.6–145.8; p < 0.01) and overall survival (77.0 months, 95%
confidence interval 47.2–106.8 vs. 153.8 months, 95% confidence interval
142.0–165.6; p = 0.01) than women with HPV-positive tumors. However, only
advanced FIGO stage and lymph node metastases remained associated with a
poor disease-free survival and overall survival on multivariate analysis. In
conclusion, our results suggest that a low percentage of cervical cancer arise
via an HPV-independent pathway. These HPV-negative tumors are diagnosed
at advanced stages, show higher prevalence of lymph nodes metastases and
have an impaired prognosis.
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Introduction
Cervical cancer is the fourth most common cancer in women worldwide and is
one of the leading causes of morbidity and mortality [1]. Human
papillomaviruses (HPV), specifically high-risk genotypes, have been identified
as the causative agents for the development of this tumor [2, 3]. Indeed, HPV is
identified in virtually all cervical cancer and premalignant cervical lesions (high
grade intraepithelial lesions/cervical intraepithelial neoplasia grade 2-3
[HSIL/CIN2-3] and adenocarcinoma in situ) [2, 3, 4, 5, 6, 7, 8]. However,
despite the development of highly sensitive tests for molecular detection of HPV
in recent years [9, 10, 11, 12, 13] and irrespectively of the technique used for
HPV detection, a small proportion of cervical cancer are consistently negative







Interestingly, two carcinogenetic pathways have been clearly characterized in
other anatomical areas in which HPV is involved in carcinogenesis such as the
vagina [17], the vulva [18], and the head and neck region [19, 20]. In all these
anatomical regions, a variable proportion of tumors are associated with HPV,
whereas the remaining cases arise through mechanisms independent of HPV.
Remarkably, in anatomical locations other than the uterine cervix, HPV-
associated carcinomas have consistently shown a better prognosis than HPV-
independent tumors [17, 18, 19, 20]. In contrast, it has not been conclusively
established whether HPV-negative carcinomas in the uterine cervix are a distinct
subset of tumors with different epidemiologic and biologic behavior, as
suggested by some reports [15], or whether they merely represent false negative
results of HPV detection techniques. Neither is there any clear evidence showing
that these tumors have different clinical and prognostic characteristics.
Therefore, it is necessary to provide more insight into the clinical and
pathological characteristics of this unusual group of cervical cancers which are
negative for HPV. In the present study, we aimed to analyze HPV status in a
large series of cervical cancer using a highly sensitive polymerase chain reaction
(PCR) technique and p16 immunohistochemical analysis, a surrogate marker of




The study included all women admitted to the Gynecological Oncology Unit of
the Hospital Clinic from Barcelona who fulfilled the following inclusion criteria:
(1) histological diagnosis of cervical cancer; (2) a paraffin block from the tumor
with available tumor tissue for HPV-DNA testing and p16 immunostaining.
From January 2012 to December 2015, 217 women with a diagnosis of cervical
cancer were identified. One case was reclassified as endometrial
adenocarcinoma after histological review. Two cases in which no material was
available for molecular analysis were excluded. Thus, 214 samples were finally
included in the study.
Demographic and clinico-pathological features (age, smoking habit, clinical
presentations, histological type, International Federation of Gynecology and
Obstetrics [FIGO] stage and nodal status) and follow-up data were recorded. The
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study was approved by the Ethics Committee of Clinical Research of the
Hospital Clinic (registry HCB/2015/0517).
Study protocol
Upon referral, all women underwent a complete clinical evaluation by a
gynecological oncologist following the clinical protocols of the Gynecological
Oncology Unit of our center. In the first visit, a biopsy of the tumor was
performed for histological confirmation, a thorough clinical examination was
made to determine the FIGO stage, and a complete blood analysis and pre-
treatment imaging evaluation (abdominopelvic magnetic resonance imaging
and/or computerized tomography scan) were performed. The imaging evaluation
was performed by a radiologist with expertise in gynecological oncology in
order to confirm the primary location of the tumor in the uterine cervix.
Clinical management and treatment
Women with stage IA1 tumors underwent the loop electrosurgical excision
procedure or extra-fascial hysterectomy. Patients with stages IA2, IB1, or IIA
underwent laparoscopy with an intraoperative sentinel lymph node evaluation.
Patients with negative sentinel lymph nodes were treated with either radical
vaginal hysterectomy assisted by laparoscopy or radical trachelectomy, while
patients with positive sentinel nodes underwent selective pelvic and complete
para-aortic lymphadenectomy without hysterectomy, followed by chemo-
radiotherapy. Patients with FIGO stage IB2, IIB, or III underwent a complete
para-aortic lymphadenectomy with selective pelvic lymphadenectomy removing
all suspicious or enlarged lymph nodes, followed by chemo-radiotherapy. A
systematic pelvic lymphadenectomy was not part of the routine procedure as
pelvic lymph nodes are included within the radiation field in women with locally
advanced cervical cancer. However, selective excision of pelvic lymph nodes
was performed on identification of enlarged lymph nodes by imaging techniques
or during the surgical procedure. Women with disseminated disease (Stage IV)
were treated with chemo-radiotherapy or palliative treatment.
Chemo-radiotherapy was administered simultaneously with radiation therapy.
All patients received brachytherapy and external beam radiation to the pelvic
region and to the aortic area if metastasic para-aortic lymph nodes.
Histological evaluation and immunohistochemical detection
of p16 and p53
All the specimens from the cervix and/or the lymph nodes were retrieved for
histological evaluation. The samples had been routinely formalin-fixed and
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paraffin-embedded. A gynecological pathologist evaluated all the cases. The
histological diagnosis was based on hematoxylin and eosin (H&E)
morphological criteria, but immunostaining (vimentin estrogen receptors,
cytokeratins 7 and 20, carcinoembryonic antigen, etc.) were used when
necessary to exclude secondary cervical involvement by other neoplasms.
Immunohistochemical analysis was performed with the Autostainer Link 48
(Dako Co., Carpinteria, CA, USA), using the EnVision system (Dako).
All tumors were stained with p16 (CINtec Histology Kit, clone E6H4; Roche-
Mtm-Laboratories, Heidelberg, Germany). Only cases with diffuse and strong
nuclear and cytoplasmic staining in all viable tumor cells were considered
positive for p16, whereas cases with irregular or focal staining were considered
negative. Keratotic areas were excluded from the p16 evaluation.
Immunostaining detection of p53 was only performed in tumors with negative
HPV-DNA testing (clone DO–7; Dako). p53 staining was scored as normal
(p53n), probably representing a “wild-type” protein, when at least a few nuclei
of the tumor cells showed weak to moderate staining comparable to the staining
pattern observed in the adjacent normal tissue. Two staining patterns were
defined as “p53 abnormal” (p53abn) and suggestive of mutated p53: (i) strong
overexpression of all tumor cells, and (ii) completely absent staining in the
tumor cells, with a positive internal control showing a wild-type pattern [22, 23,
24].
Tissue preparation and nucleic-acid isolation
DNA extraction and HPV genotyping was performed in formalin-fixed and
paraffin-embedded tissue of either the pre-treatment biopsy or the surgical
specimen. The samples were serially sectioned with a microtome. The first and
last sections (3 µm) were stained with H&E for histological confirmation of the
diagnosis. In between sections were collected in RNAase-free reaction tubes for
DNA isolation (sandwich cutting technique). Sectioning and sample preparation
were carried out with the highest measures to avoid contamination and cross-
contamination. Paraffin blocks lacking tissue were cut in between the patient
samples as controls to ensure the lack of contamination.
DNA was extracted by overnight incubation in 20 µL of proteinase K solution
(1 mg/mL) at 56 °C. Subsequently, proteinase K was heat-inactivated by
incubation of the sections at 95 °C for 10 min, and samples were spun down and
cooled down at −20 °C for 1–2 min. DNA was isolated using a commercially
available kit (QIAamp Tissue Kit; Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. DNA yields were quantified spectrophotometrically
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using the NanoDrop ND–1000 (Thermo Scientific NanoDrop, Wilmington, DE,
USA).
DNA amplification for HPV detection and genotyping
To assess the quality of the DNA, β-globin PCR analysis was performed using
the primers BGPCO3 and BGPCO5, as described elsewhere [15]. PCR products
were analyzed by electrophoresis on a 1.5% agarose gel. All samples were β-
globin PCR-positive, indicating adequate DNA quality.
A volume of 10 µL of isolated DNA were used for PCR amplification, using the
SPF10-LiPA system (Fujirebio, Gent, Belgium) as described previously [25, 26].
HPV typing was performed using the INNO-LiPA HPV Genotyping Extra II kit
(Fujirebio, Ghent, Belgium). This system allows the amplification and typing of
high-risk-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68),
probably high-risk-HPV types (26, 53, 66, 70, 73, and 82) and low-risk-HPV
types (6, 11, 40, 42, 43, 44, 54, 61, 62, 67, 81, 83, 89). Each run contained
negative and positive controls to monitor the efficiency of DNA isolation, PCR
amplification, hybridization, and genotyping procedures. None of these negative
control samples were positive in the HPV PCR assay, indicating adequate
avoidance of contamination.
Finally, a subset of eight HPV-negative tumors were tested for the presence of
high-risk-HPV E7 DNA using a sensitive E7 multiplex PCR, enabling the
detection of 14 high-risk-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68) [27].
Data analysis
The SPSS 23.0 (SPSS, Chicago, IL, USA) statistical package was used for the
statistical analysis. Categorical variables were expressed as absolute numbers
and percentages. The chi-square exact test was used to compare qualitative
variables. Quantitative variables were expressed as means and standard
deviation, and the T test was used for comparisons. For data analysis, FIGO
stages IA1 to IB1 were considered as early FIGO staging and FIGO stages IB2
to IV were referred as advanced FIGO staging. Disease-free survival was
defined as the time from diagnosis to the first local recurrence or metastasis.
Overall survival was defined as the time from the date of diagnosis to the date of
death or to the last date of follow-up. Death without documented progression
was censored at the date of death. Survival data were analyzed with the Kaplan–
Meier method, and survival curves were compared using the log-rank test and
the level of significance adopted was 0.05. Univariate and multivariate Cox
models were used to analyze prognostic factors (histology, HPV status, p16
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staining, FIGO stage and lymph node status). The hazard ratio with a 95%
confidence interval was calculated for risk estimation. The multivariate Cox
model included variables that showed statistical significance in the univariate
models.
Results
Twenty-one out of the 214 tumors (10%) included were negative for HPV DNA.
Table 1 shows the comparison between the clinical and pathological
characteristics of the patients with HPV-negative and -positive cervical cancer.
Patients with HPV-negative tumors were older and were more frequently
diagnosed due to clinical symptoms such as hemorrhage or abdominal pain.
HPV-negative tumors were more frequently of the non-squamous type (9/21,
43% vs.37/193, 19%; p < 0.01) and negative for p16. HPV-negative tumors were
more frequently diagnosed at advanced FIGO stage and more frequently had
lymph node metastases. No information was available on whether these patients
attended, or not, regular cervical cancer screening.
Table 1





Age 58 (16) 51 (15) 0.04
Smokers 6 (29) 82 (42) 0.22
Clinical presentation   <0.01
 Clinical symptoms 20 (95) 119 (62)  
 Abnormal Pap smear 1 (5) 74 (38)  
Histological type   <0.01
 Squamous cell carcinoma 12 (57) 156 (80)  
 Adenocarcinoma 6 (29) 33 (17)  
 Adenosquamous
carcinoma 1 (5) 3 (2)  
 Neuroendocrine
carcinoma 2 (9) 1 (1)  
p16   <0.01









 Positive 12 (57) 186 (96)  
 Negative 9 (43) 7 (4)  
Tumor size (mm)* 55 (22.4) 36.8 (21.2) <0.01
FIGO stage   <0.01
 Early (IA-IB1) 2 (10) 83 (43)  
 Advanced (IB2-IV) 19 (90) 110 (57)  
Relapse 7 (33) 42 (22) 0.27
Lymph node metastasis 14 (67) 69 (36) <0.01
Values are given as absolute numbers and percentages or mean and standard
deviation
Table 2 shows the age, the histological type, the p16 and p53 immunostaining
patterns and the follow-up data of the 21 HPV-negative cervical cancer. HPV E7
PCR was performed in eight tumors (6/12 HPV-negative, p16 positive, and 2/9
HPV-negative, p16 positive cases). All samples tested were negative for E7
PCR.
Table 2
Molecular, histological, and clinical characteristics of the patients with HPV-negative tumors
Case Age Histologicaltype p16 p53 E7 PCR FIGO
LN
metastases Relapse
1 64 SCC, non-keratinizing − nm np IIIB Yes No
2 57 SCC,sarcomatoid − nm np IVA Yes No
3 83 SCC, non-keratinizing − abn np IIIB Yes No
4 69 Neuroendocrinecarcinoma − abn np IVB Yes No
5 85 SCC, non-keratinizing − nm np IIIA Yes Yes
6 51 Neuroendocrinecarcinoma − nm np IIIB Yes No
7 49 ADC, mucinous − abn Negative IIIB Yes Yes
LN lymph node, SCC squamous cell carcinoma, ADC adenocarcinoma, ANED alive with 




All adenocarcinomas were of the conventional mucinous type and ten out of the
12 (83%) squamous cell carcinomas were non-keratinizing. Out of the 21
tumors, 9 (43%) showed negative p16 staining and 15/21 (71%) HPV-negative
tumors showed a p53abn immunostaining pattern. No clinical or histological
differences were found between HPV-negative/p16 positive tumors vs. p16
negative staining or between a p53nm vs. p53abn immunostaining pattern (data
not shown). Nevertheless, patients with HPV-negative/p16 positive tumors more
frequently showed a p53abn immunostaining pattern compared with HPV-
negative/p16 negative specimens (10/12, 83% vs. 5/9, 56%; p = 0.01).
Case Age Histologicaltype p16 p53 E7 PCR FIGO
LN
metastases Relapse
8 41 ADC, mucinous − abn np IIB No No
9 61 SCC,keratinizing − abn Negative IIB Yes Yes
10 53 SCC, non-keratinizing + abn np IIIB No No
11 54 ADC, mucinous + abn np IIIB Yes No
12 36 Adenosquamouscarcinoma + nm Negative IIB No No
13 82 ADC, mucinous + abn np IIIB Yes No
14 38 SCC, non-keratinizing + abn np IB1 No No
15 53 SCC, non-keratinizing + abn np IIIB Yes No
16 32 ADC, mucinous + abn Negative IB1 No No
17 64 SCC, non-keratinizing + abn Negative IIB Yes Yes
18 40 SCC, non-keratinizing + abn Negative IIIB No Yes
19 66 ADC, mucinous + nm Negative IVB Yes Yes
20 54 SCC, non-keratinizing + abn np IIB No Yes
21 80 SCC, non-keratinizing + abn Negative IVA Yes No
LN lymph node, SCC squamous cell carcinoma, ADC adenocarcinoma, ANED alive with 
alive with disease, DOD died of disease, nm p53 normal, abn p53 abnormal, np not perfo
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The median follow-up was 61 months (95% confidence interval 54.5–67.5
months). Figure 1 shows the disease-free survival (Fig. 1a) and the overall
survival (Fig. 1b) of the patients included in the study according to HPV status.
Patients with HPV-negative cervical cancer had a significantly worse disease-
free survival (59.8 months [95% confidence interval: 32.0–87.6] vs. 132.2
months [95% confidence interval: 118.6–145.8]; p < 0.01) and overall survival
(77.0 months [95% confidence interval 47.2–106.8] vs. 153.8 months [95%
confidence interval 142.0–165.6]; p = 0.01) than women with HPV-positive
tumors.
Fig. 1
Kaplan–Meier analysis of human papillomavirus (HPV) status in all the cases
included in the study. HPV-negative cases include 21 patients and HPV-positive
cases include 193 patients. a Disease-free survival (time from diagnosis to the first
local recurrence or metastasis); b Overall survival (time from the date of diagnosis
to the date of death or to the last date of follow-up). Deaths without documented
progression were censored at the date of death. Survival curves were compared
using the log-rank test
The results of the univariate and multivariate analysis for disease-free
progression and mortality are shown in Tables 3 and 4, respectively. HPV
negativity, p16 immunostaining negative, advanced FIGO stage, and lymph node
metastases were associated with a poor disease-free survival and increased
tumor-associated mortality in the univariate analysis. However, only the FIGO
stage and lymph node metastases remained associated with a poor disease-free




Univariate and multivariate Cox models for relapse
 Univariate Cox model Multivariate Cox model
 HR 95% CI p HR CI 95% p
Non SCC histology 0.9 0.5–1.6 0.85 — — —
Negative HPV status 2.4 1.3–4.4 <0.01 1.1 0.5–2.5 0.81
p16 negativity 2.9 1.5–5.8 <0.01 1.7 0.8–3.9 0.18
Advanced FIGO stage 5.8 3.0–11.3 <0.01 3.6 1.7–7.5 <0.01
Lymph node metastasis 4.1 2.5–6.6 <0.01 2.4 1.4–4.0 <0.01
HR hazard ratio, CI confidence interval
Table 4
Univariate and multivariate Cox models for mortality
 Univariate Cox model Multivariate Cox model
 HR 95% CI p HR CI 95% p
Non SCC histology 0.7 0.3–1.5 0.35 — — —
Negative HPV status 2.5 1.2–5.1 0.01 0.9 0.4–2.3 0.44
p16 negative 3.5 1.6–7.4 <0.01 1.9 0.8–5.1 0.14
Advanced FIGO stage 43.7 6.0–316.5 <0.01 23.8 3.1–177.6 <0.01
Lymph node metastasis 7.1 3.7–13.7 <0.01 3.2 1.7–6.0 <0.01
HR hazard ratio, CI confidence interval
On analyzing squamous cell carcinomas separately, patients with HPV-negative
tumors (n = 12) were more frequently diagnosed due to clinical symptoms than
women with HPV-positive (n = 156) neoplasms and were more frequently
diagnosed at advanced FIGO staging (Table 5). Patients with HPV-negative
squamous cell carcinomas had a significantly worse disease-free survival (47.6
months [95% confidence interval: 10.5–84.7] vs. 130.7 months [95% confidence
interval: 115.5–145.9]; p < 0.01) and overall survival (70.0 months [95%
confidence interval 27.3–112.7] vs. 150.0 months [95% confidence interval
136.6–163.5]; p = 0.04) compared to women with HPV-positive tumors.
Although HPV was associated with relapse and mortality risk (Hazard Ratio:
2.9, 95% confidence interval 1.3–6.5, p < 0.01; and Hazard Ratio: 2.5, 95%
confidence interval 1.0–6.4, p = 0.05, respectively) on univariate analysis, only
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lymph node metastases and advanced FIGO staging remained associated with a
worse prognosis on multivariate analysis (data not shown).
Table 5
Clinical and histological characteristics of the patients with squamous cell carcinoma
according to HPV status
 HPV-negative (n = 12) HPV-positive (n = 156) p
Age 61 (15) 52 (15) 0.65
Smokers 4 (33) 70 (45) 0.49
Clinical presentation   <0.01
 Clinical symptoms 12 (100) 98 (63)  
 Abnormal Pap smear 0 (0) 58 (37)  
p16   <0.01
 Positive 7 (58) 151 (97)  
 Negative 5 (42) 5 (3)  
Tumor size (mm)* 54.8 (25.3) 38.2 (21.1) 0.01
FIGO stage   0.04
 Early (IA-IB1) 1 (8) 59 (38)  
 Advanced (IB2-IV) 11 (92) 97 (62)  
Relapse 5 (42) 32 (21) 0.08
Lymph node metastasis 8 (67) 62 (40) 0.06
Figures are absolute numbers and percentages or means and standard deviation
Discussion
The most relevant finding of our study is that women with HPV-negative tumors
were more frequently diagnosed at advanced stages, had a higher rate of lymph
node metastasis and an impaired disease-free survival and overall survival. In
this study, HPV-negative tumors represented a small percentage of cervical
cancer (10%). These results are in keeping with previous reports, including a
previous study conducted by our group with a smaller series of cervical cancer
[15, 28, 29, 30].
Although it is generally accepted that HPV is a necessary cause of cervical
cancer, almost all studies consistently show a proportion of tumors, ranging from





sensitivity of some HPV-testing methods when applied to formalin-fixed and
paraffin-embedded tissues is likely to be the cause of the high prevalence of
HPV-negative tumors observed in some studies [29]. Poor-quality DNA of the
tumor specimens and histological misclassification by inclusion of endometrial
neoplasms as cervical adenocarcinomas have also been proposed as possible
causes of false HPV-negative results in cervical cancer [6]. In our study, the
quality of the DNA was assessed by evaluating β-globin in all of the samples,
and all were found to be adequate. In addition, a gynecological pathologist
confirmed all the histological diagnoses after careful review, which included
imaging data and immunostaining to exclude tumors of non-cervical origin when
required. In this study, in order to exclude the possibility of false HPV negativity
due to a viral integration, we have also analyzed in a subset of samples, the
presence of HPV E7 DNA by PCR targeting E7, in addition to the detection of
the DNA of the HPV. All cases were negative for E7 DNA, confirming that they
were truly HPV negative. However, the design of our study does not allow to
conclude whether the HPV-negative cervical cancers represented the clearance
of the HPV in tumors initially HPV-associated [6] or whether they were truly
HPV-independent tumors. In any case, if HPV negativity is related to an
impaired prognosis, it should be considered for the clinical management of these
patients [33, 34].
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Several studies have shown that HPV-negative cervical cancers are mostly
adenocarcinomas, and that some specific subtypes such as clear cell,
mesonephric, or gastric-type adenocarcinomas account for most of the HPV-
negative cervical cancers [2, 16, 20, 31, 35, 36, 37]. In our study,
adenocarcinomas were indeed more frequently HPV-negative than squamous cell
carcinomas, but in contrast with previously published series [16], most were of
the conventional mucinous type. Interestingly, in our study a significant
proportion of HPV-negative cervical cancers were histologically squamous cell
carcinomas. Moreover, although HPV-negative squamous cell carcinomas are
usually considered to be very well differentiated [17, 18], most of the tumors in
our series were of the conventional non-keratinizing subtype.
As shown in other studies, most HPV-positive tumors showed a strong and
diffuse overexpression of p16 [15, 17, 18, 19, 20]. However, a significant
proportion (57%) of HPV-negative tumors were positive for p16. The absence of
the HPV E7 DNA in this subset of tumors is an additional evidence that
confirms the absence of association with HPV. Interestingly, the HPV-negative
cervical cancer with p16 overexpression showed a high rate of the p53abn
immunostaining pattern suggestive of mutation (83%), supporting the hypothesis
that, p16 overexpression in some of these cervical cancers might be induced
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independently of HPV, and this could represent a higher mutation capacity of the
tumor. Previous studies have shown a relation between the mutational status of
p53 and poor prognosis [22, 38, 39]. In our series, 15/21 (71%) patients with an
HPV-negative status presented p53abn. This mutational phenotype of the HPV-
negative cervical cancers, could explain a higher capacity of tumor deregulation,
with increased growth potential and metastasis, and a worse prognosis. These
results are in keeping with previous reports in other anatomical areas [17, 18, 19,
20, 21].
In our study, HPV-negative tumors were diagnosed at more advanced FIGO
stages and showed a higher rate of lymph node metastasis. FIGO stage and
lymph node status are considered the most important prognostic parameters for
cervical cancer [40]. In fact, it is of note that in the present series almost all the
HPV-negative tumors (19/21: 91%) were diagnosed at advanced stages, which
could justify their impaired prognosis. These data also agree with previous
studies showing that HPV-negative tumors frequently show factors of poor
prognosis [38, 41, 42] and suggest that HPV-negative tumors might be a more
aggressive subtype of cervical cancer. In this regard, a recent meta-analysis
including data from 2838 patients with cervical cancer reported in 17 different
studies concluded that HPV-positive cervical cancers have a better prognosis
[43]. The poor prognosis of HPV-negative carcinomas compared with HPV-
positive tumors has also been observed in other locations in which HPV-
associated and HPV-independent carcinomas have been described. Indeed, in the
head and neck and the vaginal region, HPV-positive tumors have consistently
shown a better prognosis than HPV-negative neoplasms [17, 18, 19].
Remarkably, in the present series, the HPV-negative squamous cell carcinomas
showed the same clinical and prognostic differences when compared with the
HPV-positive squamous cell carcinomas, that is, they were more commonly
diagnosed at an advanced stage, had a higher rate of lymph node metastasis and
an impaired disease-free survival and overall survival.
The main strength of our study is that it includes a large number of cases with
cervical cancer, and that the HPV status was evaluated using highly sensitive
PCR and immunohistochemistry techniques. The main limitation of our study is
the small number of HPV-negative cervical cancers. However, given the low
frequency of these tumors, even large referral centers are only able to retrieve a
very small number of women with these neoplasms. Thus, large multi-center
studies are warranted to confirm the impaired prognosis of this subset of cervical
cancers. Another possible limitation might be the use of formalin-fixed and
paraffin-embedded samples, which could have had an impact on the quality of
DNA, and subsequently, the results of HPV-DNA testing [15, 29, 43]. However,
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the quantity of DNA was quantified spectrophotometrically, and the quality of
the DNA was confirmed by β-globin PCR in all of the samples.
In conclusion, although further studies are required to confirm these data, our
results suggest that a low percentage of cervical cancer arise via an HPV-
independent pathway and have an impaired prognosis similar to counterparts in
other anatomical sites with both HPV-associated and independent tumors.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional
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